Navigation Links
Large lung cancer study shows potential for more targeted therapies
Date:9/9/2012

A nationwide consortium of scientists has reported the first comprehensive genetic analysis of squamous cell carcinoma of the lung, a common type of lung cancer responsible for about 400,000 deaths each year.

"We found that almost 75 percent of the patients' cancers have mutations that can be targeted with existing drugs -- drugs that are available commercially or for clinical trials," says one of the lead investigators, Ramaswamy Govindan, MD, an oncologist at Washington University School of Medicine in St. Louis and co-chair of the lung cancer group of The Cancer Genome Atlas.

The research appears online Sept. 9 in Nature.

The Cancer Genome Atlas project combines efforts of the nation's leading genetic sequencing centers, including The Genome Institute at Washington University, to describe the genetics of common tumors with the goal of improving prevention, detection and treatment. The Cancer Genome Atlas is supported by the National Cancer Institute and the National Human Genome Research Institute, both parts of the National Institutes of Health (NIH).

The other lung cancer co-chairs are the study's senior author Matthew Meyerson, MD, PhD, of the Broad Institute of Massachusetts Institute of Technology and Harvard University, and Stephen Baylin, MD, of Johns Hopkins University.

The study examined the tumors and normal tissue of 178 patients with lung squamous cell carcinoma. The investigators found recurring mutations common to many patients in 18 genes. And almost all of the tumors showed mutations in a gene called TP53, known for its role in repairing damaged DNA.

Interestingly, the researchers noted that lung squamous cell carcinoma shares many mutations with head and neck squamous cell carcinomas, supporting the emerging body of evidence that cancers may be more appropriately classified by their genetics rather than the primary organ they affect.

"We clearly see mutations in lung cancer that we see in other human cancers," says Richard K. Wilson, PhD, director of The Genome Institute at Washington University. "This reinforces something that we've been seeing in a lot of our cancer genomics work. It's really less about what type of tissue the tumor arises in lung, breast, skin, prostate and more about what genes and pathways are affected."

Current treatment for squamous cell lung cancers includes chemotherapy and radiation, but there are no drugs specifically designed to target this particular type of lung cancer. Squamous cell lung cancer is linked to smoking and responsible for 30 percent of all lung cancer cases.

"With this analysis, we are just starting to understand the molecular biology of lung squamous cell carcinoma," says Govindan, who treats patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University. "And now we have identified potential targets for therapies to study in future clinical trials."


'/>"/>

Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Worlds largest meeting of ear, nose, and throat doctors
2. Fruit flies on methamphetamine die largely as a result of anorexia
3. Men with large waists face an increased risk of frequent urination
4. Obesity in type 2 diabetes: Recommendations from guidelines are largely consistent
5. Human papillomavirus types do not replace others after large-scale vaccination
6. Largest review of management and treatment of Barretts dysplasia and adenocarcinoma
7. HIV suppression not as good as previously thought, largest study of viral-load blood tests show
8. Large Breasts Can Take Mental, Physical Toll on Teens
9. Could a larger waistline be a result of too much TV as a child?
10. Obesity, larger waist size associated with better outcomes in heart failure patients
11. OnPage Provides Secure, Rapid Response at New England’s Largest Catholic Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 19, 2017 , ... A July 5th ... weight loss surgery patients who had received a body contouring procedure reported experiencing a ... clinic Beverly Hills Physicians (BHP), which provides both types of procedures, notes that this ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Fidget”: a fun-filled, action-packed ... retired public high school music and drama teacher who was a summa cum laude ... including a “Teacher of the Year” award. After her retirement from public school, Lynn ...
(Date:7/18/2017)... Oaks, CA (PRWEB) , ... July 18, 2017 , ... ... Ph.D. scientist extracted cannabis oils, announced today that at the WORLDZ Summit, taking place ... will be speaking on the therapeutic benefits of medical cannabis for both pediatric and ...
(Date:7/18/2017)... ... July 18, 2017 , ... ClinicalTrials.gov ... Decisions Do You Need to Consider?, **An FDAnews Webinar**, Aug. 2, 2017 — ... Part 11, “Final Rule for Clinical Trials Registration and Results Information,” is a ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... on a lien basis, partners with the best medical professionals who offer the ... and pre-approves each medical professional in their network, ensuring that each patient receives ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Zymo Research Corp., also known as ,The Epigenetics Company, announced ... in a precise manner using the myDNAge ™ test. Based on ... of human genetics and biostatistics at the David Geffen School of ... Zymo Research,s proprietary DNAge ™ technology is used to analyze DNA ... ...
(Date:7/11/2017)...  The global market for liquid biopsy diagnostic and ... in 2016.  Although in early stages, the global market ... as a result of the gradual shift towards personalized ... of a significant number of new liquid biopsy tests ... biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a ... who suffer from painful intercourse and other painful pelvic pain conditions such ... to menopause. ... LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void ...
Breaking Medicine Technology: